Healthcare · 13.1

Pharmaceuticals

Quantified news impact based on deduplicated, quality-reviewed events in a single 20-day window.

Average net impact+23weighted per event

Average gross impact28absolute weighted average

Events23same period

Confidence81%model average

Raw intensity62before weighting

Previous period0net impact

Gross changeInsufficient base

Diffusion speed1.2 / day

Concentration6%

Direction disagreement19%

Source independence97%14 sources

IMPACT TREND

20-day effective impact

Positive 19 · Negative 2 · Mixed 2

+270-27

11 Jul0 events

13 Jul0 events

15 Jul0 events

16 Jul0 events

18 Jul0 events

20 Jul0 events

21 Jul0 events

23 Jul0 events

25 Jul0 events

+17

26 Jul11 events

+27

28 Jul8 events

+26

30 Jul4 events

Current periodPrevious period

TIME HORIZON

Impact duration

Immediate0%0 cumulative effective impact

Short term44%285 cumulative effective impact

Medium term49%322 cumulative effective impact

Long term7%44 cumulative effective impact

CO-IMPACT

Related industries

EVENT EVIDENCE

Events ranked by effective impact

Page 3 of 3 · 23 events

Macro0

No evidence on this page.

Industries2

Industries28 Jul, 19:26mixed

15 Pharma Firms in 2026 Fortune 500; Eli Lilly Jumps to 224th as Tirzepatide Tops Global Drug Sales

The 2026 Fortune Global 500 lists 15 pharmaceutical companies, unchanged from 2025 but with reshuffled rankings. Eli Lilly posted the largest leap, rising 112 spots to 224th, with revenue surging 44.7% to $65.179 billion and profit soaring 94.9% to $20.64 billion. Its GLP-1 drug tirzepatide generated $36.507 billion in sales, surpassing Novo Nordisk's semaglutide ($36.1 billion) to become the world's best-selling medicine. Novo Nordisk also gained 35 places, and both companies led profit margins among pharma peers.

Effective: 0
Intensity: 80
Confidence: 90%
Horizon: Medium term

Industries27 Jul, 09:22mixed

China Launches 12th Batch Drug Procurement Covering 65 Varieties with New Rules

China's 12th national drug volume-based procurement (VBP) has been launched, covering 65 varieties across therapeutic areas including hypertension, diabetes, oncology, and anti-infection. New rules include a 'zero-volume winning' mechanism that uses statistical standard deviations to set anchor prices, preventing extreme low bids. A separate channel for reference-listed drugs allows qualification without volume guarantees. Reporting by brand is fully implemented, with 45,000 medical institutions submitting demand for over 500 pharmaceutical companies, averaging 15 bidders per variety and over 50 for the most competitive.

Effective: 0
Intensity: 60
Confidence: 80%
Horizon: Short term

Companies1

Companies29 Jul, 18:53positive

Anke Bio's Wholly-Owned Unit Suhao Yiming Gets NMPA Approval for Terlipressin Acetate API

Anke Bio's wholly-owned sub-subsidiary, Shanghai Suhao Yiming Pharmaceutical Co. , Ltd. , received on July 29 the Chemical API Marketing Application Approval Notice from China's National Medical Products Administration for terlipressin acetate. The active pharmaceutical ingredient will be used to produce terlipressin preparations, which are indicated for gastrointestinal bleeding, genitourinary bleeding, postoperative bleeding, and hepatorenal syndrome.

Effective: +11
Intensity: 40
Confidence: 70%
Horizon: Short term